



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	361392	Magnesium Plus
ARTG entry for	Medicine Listed	
Sponsor	Interclinical Laboratories Pty Ltd	
Postal Address	PO Box 6474, ALEXANDRIA, NSW, 2015 Australia	
ARTG Start Date	12/04/2021	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Magnesium Plus

Product Type	Single Medicine Product	Effective Date	22/06/2022
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support energy levels in children
Maintain/support energy levels
Maintain/support energy production in children
Maintain/support energy production
Maintain/support body electrolyte balance
Maintain/support general health and wellbeing
Maintain/support general health and wellbeing in children
Maintain/support healthy teeth
Maintain/support healthy teeth in children
Maintain/support bone health
Maintain/support bone health in children
Aids/assists healthy bone development/growth/building in children
Help maintain/support bone mineralisation in children
Help maintain/support bone mineralisation
Aid/assist healthy red blood cell production in children
Aid/assist healthy red blood cell production
Maintain/support blood health in children
Maintain/support blood health
Helps maintain/support haemoglobin formation/synthesis
Helps maintain/support haemoglobin formation/synthesis in children
Maintain/support cardiovascular system health
Maintain/support healthy cardiovascular system function
Maintain/support heart health
Maintain/support immune system health
Maintain/support immune system health in children
Maintain/support healthy immune system function in children
Maintain/support healthy immune system function



Australian Government
Department of Health
Therapeutic Goods Administration

Maintain/support muscle function
Maintain/support muscle function in children
Maintain/support healthy neuromuscular system/function
Maintain/support healthy neuromuscular system/function in children
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient) in children
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
Maintain/support nerve conduction in children
Maintain/support nerve conduction
Aid/assist/helps synthesis of neurotransmitters in children
Aid/assist/helps synthesis of neurotransmitters
Maintain/support nervous system health
Maintain/support nervous system health in children
Maintain/support nervous system function
Maintain/support nervous system function in children

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to chronic fatigue syndrome.

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to serious immunological diseases.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

magnesium glycinate dihydrate	641.03 mg
Equivalent: magnesium	75 mg
menaquinone 7	10 microgram
pyridoxal 5-phosphate monohydrate	3.13 mg
Equivalent: pyridoxine	2 mg

Other Ingredients (Excipients)



Australian Government

Department of Health Therapeutic Goods Administration

Acacia
ascorbyl palmitate
Carnauba Wax
colloidal anhydrous silica
croscarmellose sodium
glycerol
glyceryl monostearate
Guar Gum
hypromellose
lecithin
magnesium stearate
maize starch
microcrystalline cellulose
purified water
Rosmarinus officinalis

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary